A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
NCT03670030
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
5
Enrollment
OTHER
Sponsor class
Stopped
Slow enrollment
Conditions
Neuroendocrine Tumors
Interventions
DRUG:
ABI-009
Sponsor
Robert Ramirez
Collaborators
[object Object]